Opens in a new tab

Dr. Chen Minhu

Chinese name: 陈旻湖
Professor, Chief Physician, Doctoral Supervisor . Gastroenterology
Professor Chen Minhu is Chief Expert and academic leader of gastroenterology at the First Affiliated Hospital of Sun Yat-sen University, and a recipient of the State Council Special Allowance. He specialises in inflammatory bowel disease and Helicobacter pylori infection, and has led national research and consensus work that shapes how these conditions are diagnosed and treated in China.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

30+ years
Gastroenterology clinical experience
500+
Peer-reviewed research publications
10+
Academic books edited

  • The Physician

About Dr. Chen Minhu

Professor Chen Minhu is Chief Expert and academic leader of gastroenterology at the First Affiliated Hospital of Sun Yat-sen University and a recipient of the State Council Special Allowance. He has devoted more than thirty years to digestive disease, with particular expertise in inflammatory bowel disease and Helicobacter pylori infection. His team studies the epidemiology, causes and treatment of Crohn's disease and ulcerative colitis in China, and he has led national research projects and consensus statements on their diagnosis and management. He has published more than five hundred papers, including more than three hundred indexed in SCI journals, and edited more than ten academic books.
1、Chief Expert and academic leader of gastroenterology at the First Affiliated Hospital of Sun Yat-sen University
2、Recipient of the State Council Special Allowance
3、Chairman of the Digestive Disease Branch of the Chinese Medical Association
4、Leader of national research projects on inflammatory bowel disease
5、Author of more than five hundred papers, including more than three hundred SCI-indexed papers
6、Recipient of the first prize of the Ministry of Education Natural Science Award

Dr. Chen Minhu ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Inflammatory bowel disease

He diagnoses and treats Crohn's disease and ulcerative colitis with individualised medical therapy, biological agents and long-term monitoring, aiming to control inflammation, heal the intestinal mucosa, prevent complications and maintain the quality of life of patients with these chronic conditions.

Helicobacter pylori infection

He studies and treats Helicobacter pylori infection and its role in peptic ulcer and gastric cancer, leading research on the bacterium's interaction with the stomach lining and on eradication strategies that reduce the risk of these diseases in high-risk populations across China.

Endoscopy and digestive disease

He performs diagnostic and therapeutic endoscopy and manages common and complex digestive diseases, from gastro-oesophageal reflux and gastritis to colorectal disease, integrating clinical assessment, laboratory tests and endoscopy to reach an accurate diagnosis and an individualised treatment plan for each patient.

More：peptic ulcer——treatment; gastro-oesophageal reflux——management; colorectal disease——endoscopy; gastric cancer——prevention; intestinal inflammation——diagnosis

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. Olamkicept Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Randomized Clinical Trial
This landmark randomized, double-blind JAMA trial led by Professor Chen Minhu evaluated olamkicept, a selective IL-6 trans-signalling inhibitor, as induction therapy for patients with active ulcerative colitis. Compared with placebo, olamkicept 600 mg produced significantly higher clinical response, clinical remission and mucosal healing rates, offering a promising new targeted treatment option for ulcerative colitis.
2. Ivarmacitinib, a Selective JAK1 Inhibitor, in Moderate-to-Severe Ulcerative Colitis: A Phase II Study
This phase II randomized trial assessed ivarmacitinib, an oral selective JAK1 inhibitor, in Chinese patients with moderate-to-severe active ulcerative colitis. The study demonstrated meaningful clinical response and mucosal healing with an acceptable safety profile, supporting oral targeted therapy as a convenient treatment option for patients whose ulcerative colitis responds poorly to conventional medicines.
3. Differentiating Intestinal Tuberculosis from Crohn’s Disease: A Diagnostic Nomogram from a 6-Year Multicenter Study
This six-year prospective multicenter study of 310 patients developed and validated two diagnostic nomograms to distinguish intestinal tuberculosis from Crohn’s disease, two conditions that look almost identical on endoscopy. Using clinical, laboratory, endoscopic, CT enterography and histological features, the models achieved over 87 percent accuracy, helping clinicians avoid misdiagnosis and choose the correct treatment.
4. Early Transmural Healing Assessed by Magnetic Resonance Enterography in Crohn’s Disease Treated with Ustekinumab
This observational study from Professor Chen Minhu’s team used magnetic resonance enterography to evaluate early transmural healing in Crohn’s disease patients receiving ustekinumab. The findings show that ustekinumab can achieve bowel wall healing beyond symptom control, providing objective imaging evidence to guide treatment decisions and long-term monitoring for patients with Crohn’s disease.
5. Role of Telemedicine in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Trials
This systematic review and meta-analysis of randomized controlled trials examined telemedicine, including remote monitoring and virtual clinics, for patients living with inflammatory bowel disease. The evidence supports telemedicine as an effective and efficient way to deliver multidisciplinary care, improve patient follow-up and maintain disease control, broadening access for people with Crohn’s disease and ulcerative colitis.
6. Adalimumab for Chinese Patients with Moderately to Severely Active Crohn’s Disease: A Randomized Trial
This randomized trial led by Professor Chen Minhu confirmed the efficacy and safety of adalimumab, an anti-TNF biologic, in Chinese patients with moderately to severely active Crohn’s disease. Treatment produced clinical remission and mucosal improvement with a favourable safety profile, supporting early biologic therapy for patients with Crohn’s disease in China and the wider region.
  • Affiliated Hospital

Where Dr. Chen Minhu practices

Guangzhou

The First Affiliated Hospital, Sun Yat-sen University

Chinese name: 中山大学附属第一医院
Founded in 1910, the First Affiliated Hospital of Sun Yat-sen University, a national comprehensive medical university hospital, holds 36 national clinical key specialties, serves 15,000 daily outpatients, achieved A++ national performance rating and pioneered the world's first ischemia-free organ transplant.
Since 1910
116 years of care
36
National key specialties
15,000+
Daily outpatient visits
327
National key specialties
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Chen Minhu?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Chen Minhu.